You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
EDTA-Induced Pseudothrombocytopenia up to 9 Months after Initial COVID-19 Infection Associated with Persistent Anti-SARS-CoV-2 IgM/IgG Seropositivity
Contributor:
Bereczki, Dániel;
Nagy, Béla;
Kerényi, Adrienne;
Nagy, Gábor;
Szarka, Krisztina;
Kristóf, Katalin;
Szalay, Balázs;
Vásárhelyi, Barna;
Bhattoa, Harjit P;
Kappelmayer, János
Published:
Oxford University Press (OUP), 2022
Published in:
Laboratory Medicine, 53 (2022) 2, Seite 206-209
Language:
English
DOI:
10.1093/labmed/lmab050
ISSN:
0007-5027;
1943-7730
Origination:
Footnote:
Description:
Abstract Platelets have a role in vascular complications of COVID-19-related viral coagulopathy. Although immune-induced thrombocytopenia has been described mostly in moderate-to-severe COVID-19, the prognostic role of platelet count in COVID-19 is still controversial. Pseudothrombocytopenia has been reported to represent COVID-19-associated coagulopathy in critical illness, and transient EDTA-dependent pseudothrombocytopenia lasting less than 3 weeks was described in a patient with severe acute COVID-19 pneumonia. In our case study, EDTA-induced pseudothrombocytopenia was still present at 9 months after an initial SARS-CoV-2 virus infection in an apparently recovered 60 year old man. The persistence of antinucleocapside and antispike antibodies 9 months after the initial infection suggests that EDTA-induced pseudothrombocytopenia may be related to anti-SARS-CoV-2 IgG or IgM antibodies. We should acknowledge the possibility that pseudothrombocytopenia may also appear in some patients after seroconversion after the launch of large-scale vaccination programs.